
Prurigo Nodularis (PN)
Description
MarketVue®: Prurigo Nodularis (PN)
The MarketVue®: Prurigo Nodularis (PN) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Prurigo Nodularis (PN) report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 20 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
• Galderma
• Sanofi
• Menlo Therapeutics / Vyne Therapeutics
• Trevi Therapeutics
• Incyte
• Kiniksa
• Celldex Therapeutics
Key drugs mentioned:
• Methotrexate
• Gabapentin
• Dupilumab (Dupixent)
• Nemolizumab (Nemluvio)
• Nalbuphine HCl (Haduvio)
• INCB054707
• Vixarelimab
• CDX-0159
• Serlopitant
• INCB054707
• CDX-0159
Please note: the online download version of this report is for a global site license.
Table of Contents
24 Pages
- 1. DISEASE OVERVIEW
- A rare and chronic inflammatory condition causing itchy nodules on the skin
- Figure 1.1 – “Itch-and-scratch” cycle
- PN is largely an idiopathic condition
- Figure 1.2 – Percentage of PN patients with idiopathic disease
- Table 1.1 – Comorbidities associated with PN
- Quality of life and psychosocial impact of PN on patients
- Figure 1.3 – Percentage of patients experiencing various negative impacts of PN
- 2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease definition
- Figure 2.1 – G6 diagnosed prevalent cases of PN by region
- Table 2.1 – Diagnosed prevalent and drug-treated populations of PN in the U.S. and EU5
- PN diagnosis and drug-treatment rates are exceptionally high
- Figure 2.2 – Dermatologist-reported segmentation of PN population by disease severity
- 3. DIAGNOSIS AND CURRENT TREATMENT
- Diagnosis overview
- Figure 3.1 – Diagnostic journey for PN patients
- Lack of FDA-approved treatments for PN
- Treatment overview
- Table 3.1 – Treatment goals for PN
- Figure 3.2 – Dermatologists rating the effectiveness of and satisfaction with current PN therapies
- Current treatments for PN
- Figure 3.3 – Patient share and physician use of current treatments in PN
- Table 3.2 – Upsides and downsides of current treatments used for PN
- Current treatments for PN
- Figure 3.4 – Percentage of dermatologists who treat PN and their PN patient load
- Figure 3.5 – Treatment decision tree for PN
- Dermatologists’ opinions on current treatments
- Off-label Dupixent use to treat PN
- Figure 3.6 – Treatment dynamics of Dupixent use in PN
- Key treatment dynamics that shape disease management and drug use in PN
- Table 3.3 – Must-know PN treatment dynamics for now and the future
- Figure 3.7 – Percentage of PN patients that are eligible for a biologic or advanced systemic
- New therapies for PN likely to arrive to the market as label expansions of current therapies
- Figure 3.8 – Important dynamics of PN market evolution
- 4. UNMET NEEDS
- Overview
- Figure 4.1 – Top unmet needs in PN
- Figure 4.2 – Dermatologist-reported unmet needs in PN
- Physician perspectives on unmet needs in PN
- Figure 4.3 – U.S. dermatologists’ ranking of the need for new treatments in dermatology
- 5. PIPELINE ANALYSIS
- Figure 5.1 – Number of clinical stage therapies addressing unmet needs in PN
- Figure 5.2 – Percentage of dermatologists selecting attribute among their top three influencers of treatment selection in PN
- Dermatologists are excited about biologics and other mechanisms of action for PN
- Table 5.1 – Dermatologists’ rating of how “promising” emerging therapies are on a scale of 1-7
- Table 5.2 – Emerging PN therapies, Phase 1 to Phase 3
- Dupixent and nemolizumab are out front and poised to compete for first-line biologic use in PN
- Figure 5.3 – Differentiation between Dupixent and nemolizumab in PN
- Figure 5.4 – Comparison of reduction of itch (WI-NRS) of pipeline agents in moderate-to-severe PN
- 6. VALUE & ACCESS
- Overview
- Figure 6.1. Commercial insurance restrictions on Dupixent’s use in atopic dermatitis
- Figure 6.2. Dupixent monthly copay payments of Medicare and commercially-insured patients
- 7. METHODOLOGY
- Primary market research approach
- Epidemiology methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.